"Afana Biotech" has completed a $50 million Series A financing round.

36Kr has learned that recently, Afana Biotech announced the completion of the first closing of its Series A financing. The total size of the Series A financing reaches 50 million US dollars. The first tranche of the financing is led by Sinocapital, co-led by the life health company under Hefei Industrial Investment Group, Chantou Guozheng, and Anhui Ceyuan Industrial Investment Co., Ltd. Additional investment comes from the Venture Capital Guidance Fund under Hefei Industrial Investment Group, with Nanjing Hongjing, Shenzhen Jiurong and Shanghai Qinli participating as follow-on investors. HY Capital acts as the exclusive financial advisor. The proceeds from this round of financing will be mainly used to accelerate the efficient advancement of Afana Biotech's core pipelines such as in vivo CAR-T and tumor vaccines, continuously iterate the TALENT® technology platform, and further enhance the company's comprehensive capabilities in CMC, regulatory registration and development, and industrialization.